Genalyte
Manufacturing Ā· California, United States Ā· 51-200 Employees
View Company Info for Free
Overview
Headquarters
11095 Flintkote Ave Ste A, San Diego, Ca...Phone Number
(858) 956-1200Website
www.genalyte.comRevenue
$33.3 MillionIndustry
About Genalyte
Genalyte Org Chart
Is Genalyte your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Genalyte has recently received funding, and reach out quickly before it becomes old news!
Check out if Genalyte is spiking on competitors!
Earning: See what the market has to say on Genalyte recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Genalyte launches new products
Funding: Get notified immidiatlly once Genalyte has new funding data
Click to see if Genalyte had a recent Job posting/layoffs
Genalyte, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Genalyte
Website visits: Recent activity has been detected on your website
Recommended Actions
Find VP level buyers at Genalyte
Find 2 more new buyers
Compare Similar Companies to Genalyte
Compare insights from companies similar to Genalyte, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Genalyte is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Genalyte is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Genalyte.
Genalyte financials insights
Gather financial insights about Genalyte, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
Series B
$11.8M
Series C
$44M
Private Equity
$36M
Unspecified
$50M
Genalyte Tech Stack
A closer look at the technologies used by Genalyte
Most Recent Scoops
Genalyte News & Media
Genalyte Announces Oversubscribed $50 Million Financing Round to Expand Testing Menu and Deploy Platform
SAN DIEGO, Jan. 11, 2021 /PRNewswire/ -- Genalyte, a leading diagnostics and analytics company, announced today the closure of $50 million in financing. Genalyte's Maverick⢠Diagnostic System (MDS) uses silicon chip based photonic ring resonance technology to perform multiple,...San Diego's Genalyte Granted Emergency Approval for COVID-19 Antibody Test
San Diego-based healthcare diagnostics company Genalyte has received Emergency Use Authorization from the U.S. Food and Drug Administration for its rapid COVID-19 antibody test, the company announced Thursday.Genalyte Obtains FDA Emergency Use Authorization for Rapid COVID-19 Antibody Test
SAN DIEGO, Oct. 15, 2020 /PRNewswire/ -- Genalyte, a leading point-of-care diagnostics and analytics company, announced today its SARS-CoV-2 Multi-Antigen Serology Panel has received Emergency Use Authorization (EUA) from the FDA. The panel tests for the detection of IgG and IgM...Genalyte Expands Testing Capabilities to Houston With COVID-19 Antibody Testing
SAN DIEGO, July 14, 2020 /PRNewswire/ -- Genalyte, the company empowering physicians and patients with real-time diagnostics and healthcare analytics, today announced its SARS-CoV-2 Multi-Antigen Serology Panel, is now available in Houston. Genalyte's antibody testing site will be located...
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Genalyte
Genalyte provides an innovative on-site blood testing platform that delivers real-time lab results in under 30 minutes, enhancing the efficiency of diagnostics. Their product, Merlin, integrates seamlessly into existing workflows, allowing healthcare providers to receive actionable results while patients are still in the waiting room. Targeting pri... Read More